Immunogenicity of engineered antibodies.

By W. Y. Hwang, J. Foote. Methods, 2005

612 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antibody Structure and Function: The Basis for Engineering Therapeutics (2019, background): “In many cases, chimeric antibodies demonstrated reduced immunogenicity but still elicited some human anti-therapeutic antibody response [93].”
Potent antibody therapeutics by design (2006, background): “Immunogenicity data for chimeric humanized mouse antibodies strongly indicate that the replacement of mouse-antibody constant domains with human-antibody constant domains substantially reduces the immunogenicity of the antibody and that humanization might further reduce the immunogenicit”
The immunogenicity of humanized and fully human antibodies (2010, background): “Whereas approximately 40% of chimeric antibodies containing human sequence-derived constant regions and murinesequence derived V regions induce marked anti-drug antibody responses in vivo, only 9% of humanized and antibodies containing human constant regions and human sequence derived VH and VL fram”
Mining human antibody repertoires (2010, background): “Human and humanized mAbs have been found to be less immunogenic than nonhuman and chimeric mAbs, the latter of which trigger human anti-mouse antibody (HAMA), human anti-rat antibody (HARA) and human anti-chimeric antibody (HACA) responses.(1) It is expected, but remains to be substantiated, that hu”